Osang Healthcare announced on the 18th that it will begin U.S. clinical trials for its point-of-care molecular diagnostic device, the GeneFinder MX1, starting in October. The trials will be conducted in collaboration with U.S.-based Kryptos Biotechnologies, a strategic investment partner, with completion expected by the first quarter of 2026.

The GeneFinder MX1, a point-of-care molecular diagnostics (POC-MDx) device, is the world's first product to incorporate photothermal PCR technology, which generates heat using light and precisely controls it. This technology dramatically reduces the time required for the gene amplification process, enabling results to be confirmed on-site within 20 minutes (maximum 30 minutes).

Furthermore, this all-in-one cartridge type device automatically performs the entire process—from sample pretreatment and nucleic acid extraction to amplification and result analysis—without manual intervention once medical staff collect the sample and insert it into the cartridge. By simply using the appropriate cartridge for the disease being diagnosed, it can test various samples including saliva, urine, blood, and stool.

Full Article :  https://www.yakup.com/news/index.html?mode=view&cat=12&nid=316209